Publication:
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.

dc.contributor.authorMedina-Caliz, Inmaculada
dc.contributor.authorRobles-Diaz, Mercedes
dc.contributor.authorGarcia-Muñoz, Beatriz
dc.contributor.authorStephens, Camilla
dc.contributor.authorOrtega-Alonso, Aida
dc.contributor.authorGarcia-Cortes, Miren
dc.contributor.authorGonzález-Jimenez, Andres
dc.contributor.authorSanabria-Cabrera, Judith A
dc.contributor.authorMoreno, Inmaculada
dc.contributor.authorFernandez, M Carmen
dc.contributor.authorRomero-Gomez, Manuel
dc.contributor.authorNavarro, Jose M
dc.contributor.authorBarriocanal, Ana M
dc.contributor.authorMontane, Eva
dc.contributor.authorHallal, Hacibe
dc.contributor.authorBlanco, Sonia
dc.contributor.authorSoriano, German
dc.contributor.authorRoman, Eva M
dc.contributor.authorGomez-Dominguez, Elena
dc.contributor.authorCastiella, Agustin
dc.contributor.authorZapata, Eva M
dc.contributor.authorJimenez-Perez, Miguel
dc.contributor.authorMoreno, Jose M
dc.contributor.authorAldea-Perona, Ana
dc.contributor.authorHernandez-Guerra, Manuel
dc.contributor.authorPrieto, Martin
dc.contributor.authorZoubek, Miguel E
dc.contributor.authorKaplowitz, Neil
dc.contributor.authorLucena, M Isabel
dc.contributor.authorAndrade, Raul J
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Regional Development Fund–FEDER
dc.contributor.funderAgencia Española del Medicamento
dc.contributor.funderCIBERehd
dc.contributor.groupSpanish DILI registry
dc.date.accessioned2023-01-25T08:32:35Z
dc.date.available2023-01-25T08:32:35Z
dc.date.issued2016-05-13
dc.description.abstractChronic outcome following acute idiosyncratic drug-induced liver injury (DILI) is not yet defined. This prospective, long-term follow-up study aimed to analyze time to liver enzyme resolutions to establish the best definition and risk factors of DILI chronicity. 298 out of 850 patients in the Spanish DILI registry with no pre-existing disease affecting the liver and follow-up to resolution or ⩾1year were analyzed. Chronicity was defined as abnormal liver biochemistry, imaging test or histology one year after DILI recognition. Out of 298 patients enrolled 273 (92%) resolved ⩽1year from DILI recognition and 25 patients (8%) were chronic. Independent risk factors for chronicity were older age [OR: 1.06, p=0.011], dyslipidemia [OR: 4.26, p=0.04] and severe DILI [OR: 14.22, p=0.005]. Alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin (TB) median values were higher in the chronic group during follow-up. Values of ALP and TB >1.1 x upper limit of normal (xULN) and 2.8 xULN respectively, in the second month from DILI onset, were found to predict chronic DILI (p1.1 x upper limit of normal (xULN) and 2.8 xULN respectively, in the second month from DILI onset, were found to predict chronic DILI (p One year is the best cut-off point to define chronic DILI or prolonged recovery, with risk factors being older age, dyslipidemia and severity of the acute episode. Statins are distinctly related to chronicity. ALP and TB values in the second month could help predict chronicity or very prolonged recovery. Drug-induced liver injury (DILI) patients who do not resolve their liver damage during the first year should be considered chronic DILI patients. Risk factors for DILI chronicity are older age, dyslipidemia and severity of the acute episode. Chronic DILI is not a very common condition; normally featuring mild liver profile abnormalities and not being an important clinical problem, with the exception of a small number of cases of early onset cirrhosis.
dc.description.sponsorshipThe present study has been supported by grants from the Instituto de Salud Carlos III co-funded by the European Regional Development Fund–FEDER (contract numbers: PI04/1688, PI12-00620, AC-0073-2013) and by the Agencia Española del Medicamento. CIBERehd is funded by the Instituto de Salud Carlos III.
dc.description.versionSi
dc.identifier.citationMedina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016 Sep;65(3):532-42
dc.identifier.doi10.1016/j.jhep.2016.05.003
dc.identifier.essn1600-0641
dc.identifier.pmcPMC7458366
dc.identifier.pmid27184533
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458366/pdf
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458366
dc.identifier.urihttp://hdl.handle.net/10668/10089
dc.issue.number3
dc.journal.titleJournal of hepatology
dc.journal.titleabbreviationJ Hepatol
dc.language.isoen
dc.organizationHospital Torrecárdenas
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Costa del Sol
dc.organizationHospital Universitario Regional de Málaga
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number532-42
dc.provenanceRealizada la curación de contenido 20/03/2025
dc.publisherElsevier
dc.pubmedtypeJournal Article
dc.relation.projectIDPI04/1688
dc.relation.projectIDPI12-00620
dc.relation.projectIDAC-0073-2013
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S0168-8278(16)30188-X
dc.rights.accessRightsRestricted Access
dc.subjectChronic
dc.subjectHepatotoxicity
dc.subjectRisk factors
dc.subjectStatins
dc.subject.decsDislipidemias
dc.subject.decsHistología
dc.subject.decsAlanina Transaminasa
dc.subject.decsFibrosis
dc.subject.decsInhibidores de Hidroximetilglutaril-CoA Reductasas
dc.subject.meshAlanine Transaminase
dc.subject.meshChemical and Drug Induced Liver Injury
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshProspective Studies
dc.subject.meshRisk Factors
dc.titleDefinition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number65
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format